Hi-Tech Pharmacal
This article was originally published in The Tan Sheet
Executive Summary
Year-end sales rose to $56.4 mil., up 19% from the prior-year period, the company announces July 13. Net income for the fiscal year ended April 30 increased 15% to $6.6 mil., the Amityville, N.Y.-based company says. Although the Health Care Products division saw a 9% sales decrease, revenue for the DiabetiDerm line increased by 46%, which the firm attributes to strong sales of the line's foot cream containing L-Arginine. The company says it "intends to stay focused on branded products targeting the diabetes market and related areas, including podiatry and dermatology." Hi-Tech Pharmacal identified its increasing interest in products for diabetics last year (1"The Tan Sheet" Sept. 29, 2003, p. 10)...
You may also be interested in...
Hi-Tech Diabetic Products To Play Key Role In Firm’s Growth Strategy
Hi-Tech Pharmacal plans to build up its Health Care Products Division through a two-pronged approach involving launching new products aimed at diabetics and expanding distribution channels
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.